Viking Therapeutics
VKTX
Market cap $3.09B

31.11 USD

-0.18

0.58%

At close Jul 11, 4:00 PM EDT

After hours

31.23

+0.12

0.39%

1 day

-0.58%

5 days

11.31%

1 month

7.46%

3 months

40.01%

6 months

-19.98%

Year to date

-24.34%

1 year

-46.94%

5 years

363.64%

10 years

347.63%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 46

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

131% more call options, than puts

Call options by funds: $222M | Put options by funds: $96M

58% more repeat investments, than reductions

Existing positions increased: 158 | Existing positions reduced: 100

5.73% less ownership

Funds ownership: 73.6% [Q4 2024] → 67.87% (-5.73%) [Q1 2025]

9% less funds holding

Funds holding: 407 [Q4 2024] → 369 (-38) [Q1 2025]

34% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 100

44% less capital invested

Capital invested by funds: $3.3B [Q4 2024] → $1.84B (-$1.46B) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$75

141%

upside

Avg. target

$96

208%

upside

High target

$104

234%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	228%upside $102	Buy Reiterated	25 Jun 2025
Cantor Fitzgerald Steven Seedhouse	234%upside $104	Overweight Initiated	28 Apr 2025
Truist Securities Joon Lee	141%upside $75	Buy Reiterated	28 Apr 2025
Morgan Stanley Michael Ulz	228%upside $102	Overweight Maintained	24 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 25 articles about VKTX published over the past 30 days

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

The Motley Fool

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth.

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

The Motley Fool

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Most investors have written off biotech stocks as a graveyard of broken dreams. While artificial intelligence (AI) captures Wall Street's imagination, the biotech industry -- once the crown jewel of innovation -- has been left for dead.

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $850M cash and large pivotal trials underway for both injectable and oral VK2735. Viking doesn't need to outperform Lilly or Novo; meeting FDA approval thresholds could secure blockbuster status in a massive, multi-drug market.

Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

The Motley Fool

2 Beaten-Down Stocks With Massive Upside Potential

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 3.94%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period.

2 Beaten-Down Stocks With Massive Upside Potential

Zacks Investment Research

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

The Motley Fool

10 Incredible Growth Stocks Poised for Long-Term Gains

Growth stocks have been on a tumultuous ride in 2025. The confluence of geopolitical turmoil, high interest rates, the artificial intelligence (AI) superbuild, and valuation concerns has created dramatic volatility.

10 Incredible Growth Stocks Poised for Long-Term Gains

The Motley Fool

Got $200? 2 Biotech Stocks to Buy and Hold Forever

Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add value to your portfolio over time.

Got $200? 2 Biotech Stocks to Buy and Hold Forever

See News Rankings

Charts implemented using Lightweight Charts™